
Verily Life Sciences, an Alphabet Inc. subsidiary, is dedicated to life sciences research.
Verily Life Sciences, founded on December 7, 2015, is a subsidiary of Alphabet Inc. dedicated to advancing life sciences research. Initially part of Google X as Google Life Sciences, it became an independent entity under Alphabet Inc. with a focus on healthcare and biotechnology. Verily's mission is to leverage technology to improve health outcomes through precision medicine and innovative healthcare solutions. Their offerings include Onduo, a platform aimed at delivering precision care for chronic conditions, and various other projects that integrate data science and healthcare.
Notable figures associated with Verily include CEO Stephen Gillett. The company has attracted significant investment from Alphabet Inc., reflecting its strategic importance within the conglomerate. Key achievements include partnerships with leading healthcare organizations and the development of cutting-edge health monitoring tools. Despite operating losses, Verily's impact is evident in its contributions to precision medicine and its role in shaping the future of healthcare technology.

Gilead Sciences
gilead.com

Dnanexus
dnanexus.com

Insitro
insitro.com

Verge Genomics
vergegenomics.com

Revvity

23andMe
23andme.com

Insightful Science

Endpoint Health

Verana Health
veranahealth.com

Unite Genomics

Veru
verupharma.com

Verinomics
verinomics.com

Genentech
gene.com

Verisim Life
verisimlife.com

Veracyte
veracyte.com
Companies similar to Verily include Gilead Sciences, Dnanexus, Insitro and Verge Genomics.
Verily was founded in 2015.
Verily's headquarters is located in South San Francisco, CA, US.
As of Sep 28, 2022, Verily has raised a total of $3.5B (USD).
Verily has 2,023 employees as of Feb 4, 2024.